GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BSP:GILD34) » Definitions » Cyclically Adjusted PS Ratio

Gilead Sciences (BSP:GILD34) Cyclically Adjusted PS Ratio : 2.90 (As of Jun. 09, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Gilead Sciences Cyclically Adjusted PS Ratio?

As of today (2024-06-09), Gilead Sciences's current share price is R$171.83. Gilead Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was R$59.29. Gilead Sciences's Cyclically Adjusted PS Ratio for today is 2.90.

The historical rank and industry rank for Gilead Sciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

BSP:GILD34' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.68   Med: 5.47   Max: 24.58
Current: 2.7

During the past years, Gilead Sciences's highest Cyclically Adjusted PS Ratio was 24.58. The lowest was 2.68. And the median was 5.47.

BSP:GILD34's Cyclically Adjusted PS Ratio is ranked worse than
60.43% of 743 companies
in the Drug Manufacturers industry
Industry Median: 2.05 vs BSP:GILD34: 2.70

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Gilead Sciences's adjusted revenue per share data for the three months ended in Mar. 2024 was R$13.350. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is R$59.29 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Gilead Sciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Gilead Sciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cyclically Adjusted PS Ratio Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.48 3.62 3.86 4.01 3.46

Gilead Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.76 3.41 3.24 3.46 3.06

Competitive Comparison of Gilead Sciences's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted PS Ratio falls into.



Gilead Sciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Gilead Sciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=171.83/59.29
=2.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Gilead Sciences's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=13.35/131.7762*131.7762
=13.350

Current CPI (Mar. 2024) = 131.7762.

Gilead Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4.391 100.560 5.754
201409 4.314 100.428 5.661
201412 6.031 99.070 8.022
201503 7.602 99.621 10.056
201506 8.329 100.684 10.901
201509 10.771 100.392 14.138
201512 11.228 99.792 14.827
201603 10.206 100.470 13.386
201606 9.823 101.688 12.729
201609 9.111 101.861 11.787
201612 9.265 101.863 11.986
201703 7.706 102.862 9.872
201706 8.934 103.349 11.391
201709 7.733 104.136 9.786
201712 7.431 104.011 9.415
201803 6.320 105.290 7.910
201806 8.142 106.317 10.092
201809 8.796 106.507 10.883
201812 8.702 105.998 10.818
201903 7.904 107.251 9.711
201906 8.582 108.070 10.465
201909 9.110 108.329 11.082
201912 9.470 108.420 11.510
202003 10.673 108.902 12.915
202006 10.631 108.767 12.880
202009 14.082 109.815 16.898
202012 14.902 109.897 17.869
202103 14.340 111.754 16.909
202106 12.406 114.631 14.261
202109 15.521 115.734 17.672
202112 16.230 117.630 18.182
202203 12.993 121.301 14.115
202206 12.539 125.017 13.217
202209 14.641 125.227 15.407
202212 15.319 125.222 16.121
202303 13.119 127.348 13.575
202306 12.730 128.729 13.031
202309 13.850 129.860 14.054
202312 13.887 129.419 14.140
202403 13.350 131.776 13.350

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Gilead Sciences  (BSP:GILD34) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Gilead Sciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (BSP:GILD34) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences (BSP:GILD34) Headlines

No Headlines